Fol News

Tutti gli approfondimenti
Tutte le notizie

Caladrius Biosciences Inc(NASDAQ:CLBS)

Caladrius Biosciences Announces $25.0 Million Private Placement

BASKING RIDGE, N.J. (January 21, 2021) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that it has entered into securities purchase agreements with certain institutional and accredited investors to raise $25.0 million through the issuance of an aggregate 12,500,000 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 6,250,000 shares of common stock, at a purchase price of $2.00 per share of common stock (or common stock equivalent in lieu thereof) and associated warrant in a private placement priced at-the-market under Nasdaq rules. The closing of the private placement is expected to occur on or about January 25, 2021, subject to satisfaction of customary closing conditions.


H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.


The warrants have an exercise price of $2.90 per share, are exercisable immediately and have a term of five and one-half years.


The Company currently intends to use the net proceeds from the offering for working capital and general corporate purposes, including the advancement of its CD34+ technology-based clinical programs.


The offer and sale of the foregoing securities are being made in a transaction not involving a public offering and have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or applicable state securities laws. Accordingly, the securities may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.


Under an agreement with the investors, the Company is required to file an initial registration statement with the Securities and Exchange Commission covering the resale of the shares of common stock to be issued to the investors within ten calendar days and to use its best efforts to have the registration statement declared effective as promptly as practical thereafter, and in any event no later than 90 days after today in the event of a “full review” by the Securities and Exchange Commission.


This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state.
 
Mi piacerebbe sapere chi era ieri a comprare a 4,80 $ e soprattutto perché;
i volumi sono stati enormi, quindi non penso che fossero solo retails.
 
Caladrius Biosciences, Inc. Announces $65 Million Registered Direct Offerings Priced At-The-Market under Nasdaq Rules

BASKING RIDGE, N.J. (February 12, 2021) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that it has entered into securities purchase agreements with several institutional investors to purchase an aggregate of 24,906,134 shares of its common stock and warrants to purchase up to an aggregate of 12,453,067 shares of common stock at a purchase price of $2.45 per share of common stock and associated warrant in a registered direct offering priced at-the-market under Nasdaq rules. The warrants have an exercise price of $2.90 per share, will be immediately exercisable, and will expire five years from the issuance date. The registered direct offering is expected to close on or about February 17, 2021, subject to the satisfaction of customary closing conditions.


H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering to the institutional investors.


In addition, the Company also announced that it entered into a securities purchase agreement with certain accredited investors to purchase an aggregate of 1,632,652 shares of its common stock and warrants to purchase up to an aggregate of 816,326 shares of common stock in a non-brokered registered direct offering on the same terms as above. Such registered direct offering is also expected to close on or about February 17, 2021, subject to the satisfaction of customary closing conditions.


The gross proceeds from the registered direct offerings are expected to be approximately $65 million before deducting placement agent fees and other offering expenses. The Company currently intends to use the net proceeds from the offering for working capital and general corporate purposes, including the advancement of its CD34+ technology-based clinical programs.


The securities described above are being offered pursuant to a "shelf" registration statement (File No. 333-226319) filed with the Securities and Exchange Commission (SEC) and declared effective on August 2, 2018. Such securities may be offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A prospectus supplement and the accompanying prospectus relating to each of the offerings of the securities will be filed with the SEC. Electronic copies of the prospectus supplement and the accompanying prospectus relating to the offering of the securities to the institutional investors may be obtained, when available, on the SEC's website at SEC.gov | HOME or by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by e-mail: placements@hcwco.com or by telephone: (646) 975-6996.


This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor there any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.
 
Crollo verticale (-23%) del prezzo dell'azione a seguito dell'annuncio di aumento di capitale.
I nuovi soci pagano l'azione 2,45 $ e oggi in borsa è scesa a 2,08 $.
 
Un crollo senza fine quello di Caladrius.
Eppure i fondi ci hanno appena messo 65 milioni di dollari.
Davvero non capisco. Sta di fatto che sto perdendo quasi tutti i soldi investiti.
 
Caladrius Biosciences Announces Orphan Drug Designation for CLBS12 for the Treatment of Buerger’s Disease

BASKING RIDGE, N.J. (March 8, 2021) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that the U.S. Food and Drug Administration (“FDA”) has granted orphan drug designation to the Company’s CD34+ cell therapy product, CLBS12, for the treatment of Buerger’s disease – also known as thromboangiitis obliterans – a condition related to critical limb ischemia (“CLI”) with no approved treatments to date in the U.S. .


“We are very pleased that the FDA has granted orphan drug designation to CLBS12 in Buerger’s disease. Without a currently approved or effective treatment for this condition in the U.S., a significant unmet need remains for therapies that slow, stop or, ideally, reverse this debilitating disease,” stated David J. Mazzo, Ph.D., President and Chief Executive Officer of Caladrius. “The Company’s ongoing open-label, registration-eligible study of HONEDRA® (CLBS12) as a treatment for CLI and Buerger’s Disease in Japan has shown strong results to date with approximately 60% of subjects in the completed Buerger’s Disease cohort reaching a positive ‘CLI-free’ endpoint despite the natural history of continuous disease progression leading to amputation. With this designation we can now engage FDA in discussions to define the most efficient and rapid development pathway to registration in the U.S. Achieving orphan designation for CLBS12 takes us one step closer to realizing our goal of fulfilling the unmet medical need for Buerger’s Disease patients around the world.”


Orphan drug designation is granted by the FDA’s Office of Orphan Products Development, which provides orphan status to drugs or biologics that are intended to treat rare diseases or disorders that affect fewer than 200,000 people in the United States. This designation provides the sponsor of the drug certain incentives, including tax credits, for qualified clinical trials and fee waivers. Orphan Drug designation confers eligibility for seven years of market exclusivity to an orphan drug post-approval, subject to a receipt by the FDA of marketing approval.
 
Calo senza fine quello di Caladrius; davvero una grandissima delusione.
 
Non è cosi malvagio come sembra.

1) ha cash abbondante
2) warrant esercitabili a 2,90$
3) solo 27 dipendenti,
4) un'ottima pipeline : Caladrius Biosciences, Inc. - NASDAQ: CLBS
5) recentemente ha quotato quasi 5$.

Se compri adesso e se stai sul pezzo, i 5$ li rivedrai. Magari fra un anno, ma li rivedrai. Sicuro.-
 
din-don-dan ha scritto:
Non è cosi malvagio come sembra.

1) ha cash abbondante
2) warrant esercitabili a 2,90$
3) solo 27 dipendenti,
4) un'ottima pipeline : Caladrius Biosciences, Inc. - NASDAQ: CLBS
5) recentemente ha quotato quasi 5$.

Se compri adesso e se stai sul pezzo, i 5$ li rivedrai. Magari fra un anno, ma li rivedrai. Sicuro.-
Clicca per espandere...


Guarda, io ormai con questo titolo ho perso quasi tutto il capitale investito; per andare pari, dovrebbe risalire sino a 57 $.
La tengo in portafoglio come memoria degli errori commessi.
 
Implacabile ha scritto:
Guarda, io ormai con questo titolo ho perso quasi tutto il capitale investito; per andare pari, dovrebbe risalire sino a 57 $.
La tengo in portafoglio come memoria degli errori commessi.
Clicca per espandere...

Sai quanti errori ho fatto io che sono vecchiotto, che opero da 50 anni e che DEVO imparare ancora????

Probabilmente non le imparerò più e lascio i miei appunti (una montagna) a chi verrà dopo.
 
aladrius Biosciences to Assess its CLBS201 CD34+ Cell Therapy in Diabetic Kidney Disease

FDA authorizes new IND for the study of CLBS201 in patients with reduced kidney function

BASKING RIDGE, N.J. (June 22, 2021) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that the U.S. Food and Drug Administration (“FDA”) has authorized its investigational new drug (“IND”) application for the study of CLBS201, a CD34+ cell therapy for the treatment of diabetic kidney disease (“DKD”).

“Our latest development program, CLBS201, is designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for diabetic patients with reduced kidney function. Specifically, we will be targeting patients with later stage chronic kidney disease. Based on a wealth of published preclinical and early clinical data, it appears that the innate ability of CD34+ cells to promote the growth of new microvasculature could be a means to attenuate the progression, or even reverse the course, of DKD,” stated David J. Mazzo, Ph.D., President and Chief Executive Officer of Caladrius. “We plan to initiate a phase 1/2 proof-of-concept study of CLBS201 within the next several months. Kidney disease remains a largely unmet medical need, especially as the general population ages and the incidence of diabetes and hypertension increases.”
 
Sempre più giù; siamo vicinissimi ai minimi storici; davvero un pessimo titolo e io ci ho investito.
Mi domando se potrà mai esserci un futuro per Caladrius, un futuro che non sia il fallimento.
 
E' davvero triste essere azionisti di Caladrius, siamo ai minimi storici e non si vede nulla all'orizzonte.
 
Devi accedere o registrarti per poter rispondere.
Indietro